EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention

Inclusion Criteria: 1. Age ≥18 and \<80 years old. 2. Males and females at birth. 3. Baseline LDL-Cholesterol: * ≥ 130 mg/dl (in statin-naïve patients or who have not followed a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment) or * ≥110 mg/dl (in patients who have received stable moderate-intensity or low-intensity statin treatment in the 4 weeks prior to enrollment) or * ≥100 mg/dl (in patients who have received stable treatment with high-intensity statins in the 4 weeks prior to enrollment) 4. Discharged at home 5. Ability to understand the requirements of the study and to provide informed consent Exclusion Criteria: 1. Patients who have previously received or currently treated with PCSK9i (evolocumab or alirocumab) or siRNA (inclisiran) 2. Unstable clinical status (hemodynamic or electrical instability) 3. Uncontrolled cardiac arrhythmias, defined as recurrent, symptomatic ventricular tachycardia or atrial fibrillation or flutter with rapid ventricular response 4. Severe renal dysfunction, defined by eGFR \< 30 mL/min/1.73 m2 5. Active liver disease or liver dysfunction, reported in the medical record or defined by AST or ALT levels \> 3 times the upper limit of normal. 6. Reported intolerance to statins defined by the following criteria: inability to tolerate at least two different statins; intolerance associated with confirmed and intolerable statin-related adverse effects or significant biomarker abnormalities; improvement/resolution of symptoms or biomarkers following dose decrease or discontinuation; symptoms or changes in biomarkers not attributable to established predispositions. 7. Treatment with systemic steroids or systemic cyclosporine within the past 3 months (e.g., intravenously, intramuscularly, or orally) 8. Known active infection or severe hematologic, metabolic, or endocrine dysfunction as judged by the Investigator. 9. Current inclusion in other pharmacological and non-pharmacological experimental studies. 10. Pregnancy. For women of childbearing potential (age \< 50 years and last menses \<12 months prior to screening) who have not undergone tubal ligation, oophorectomy, or hysterectomy, pregnancy will be excluded from a pregnancy test prior to inclusion in the study. 11. Active neoplasia or very severe disease compromising short-medium term life expectancy. Only for sites randomized to the interventional group: • Patients without a device suitable for App use (eg. Smartphone or tablet) or patients that do not consent to receive push notifications by the App.